PMID- 35081304
OWN - NLM
STAT- MEDLINE
DCOM- 20220808
LR  - 20221201
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 46
IP  - 4
DP  - 2022 Jul
TI  - Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients 
      with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
PG  - 630-639
LID - 10.4093/dmj.2021.0130 [doi]
AB  - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with chronic 
      kidney disease (CKD). However, the causal relationship between NAFLD and CKD is 
      uncertain, particularly in patients with type 2 diabetes mellitus (T2DM). We 
      aimed to investigate the association between the presence and severity of NAFLD 
      and incident CKD in patients with T2DM. METHODS: In this longitudinal cohort 
      study of patients with T2DM, 3,188 patients with preserved renal function were 
      followed up for the occurrence of incident CKD. NAFLD was defined as the presence 
      of hepatic steatosis on ultrasonography, without any other causes of chronic 
      liver disease. Advanced liver fibrosis of NAFLD was defined as a fibrosis-4 index 
      >/=2.67. CKD was defined as an estimated glomerular filtration rate <60 mL/min/1.73 
      m2. RESULTS: At baseline, 1,729 (54.2%) patients had NAFLD, of whom 94 (5.4%) had 
      advanced liver fibrosis. During the follow-up of 8.3+/-3.6 years, 472 (14.8%) 
      patients developed incident CKD: 220 (15.1%) in the non-NAFLD group, 231 (14.1%) 
      in the NAFLD without advanced fibrosis group and 28 (31.1%) in the NAFLD with 
      advanced fibrosis group. There was no increased risk of incident CKD in the NAFLD 
      group compared to the non-NAFLD group (P=0.435). However, among patients with 
      NAFLD, advanced liver fibrosis was associated with an increased risk of CKD 
      (adjusted hazard ratio, 1.75; 95% confidence interval, 1.15 to 2.66; P=0.009). 
      CONCLUSION: Advanced liver fibrosis in patients with NAFLD is independently 
      associated with an increased risk of incident CKD in patients with T2DM.
FAU - Seo, Da Hea
AU  - Seo DH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Suh, Young Ju
AU  - Suh YJ
AD  - Department of Biomedical Sciences, Inha University College of Medicine, Incheon, 
      Korea.
FAU - Cho, Yongin
AU  - Cho Y
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Ahn, Seong Hee
AU  - Ahn SH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Seo, Seongha
AU  - Seo S
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Hong, Seongbin
AU  - Hong S
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Lee, Yong-Ho
AU  - Lee YH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Choi, Young Ju
AU  - Choi YJ
AD  - Huh's Diabetes Center, Seoul, Korea.
FAU - Lee, Eunjig
AU  - Lee E
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Kim, So Hun
AU  - Kim SH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220126
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
SB  - IM
CIN - Diabetes Metab J. 2022 Jul;46(4):564-566. PMID: 35929174
CIN - Diabetes Metab J. 2022 Nov;46(6):953-955. PMID: 36455532
CIN - Diabetes Metab J. 2022 Nov;46(6):956-957. PMID: 36455533
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Humans
MH  - Liver Cirrhosis/complications/epidemiology
MH  - Longitudinal Studies
MH  - *Non-alcoholic Fatty Liver Disease/complications/epidemiology
MH  - *Renal Insufficiency, Chronic/complications/epidemiology
PMC - PMC9353562
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Fibrosis
OT  - Liver
OT  - Non-alcoholic fatty liver disease
OT  - Renal insufficiency, chronic
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2022/01/27 06:00
MHDA- 2022/08/09 06:00
PMCR- 2022/07/01
CRDT- 2022/01/26 18:28
PHST- 2021/06/23 00:00 [received]
PHST- 2021/10/24 00:00 [accepted]
PHST- 2022/01/27 06:00 [pubmed]
PHST- 2022/08/09 06:00 [medline]
PHST- 2022/01/26 18:28 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - dmj.2021.0130 [pii]
AID - dmj-2021-0130 [pii]
AID - 10.4093/dmj.2021.0130 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2022 Jul;46(4):630-639. doi: 10.4093/dmj.2021.0130. Epub 2022 
      Jan 26.